Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab

Besbas N., Gulhan B., Karpman D., Topaloglu R., Duzova A., Korkmaz E., ...Daha Fazla

PEDIATRIC NEPHROLOGY, cilt.28, sa.1, ss.155-158, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00467-012-2296-4
  • Dergi Adı: PEDIATRIC NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.155-158
  • Anahtar Kelimeler: Atypical hemolytic uremic syndrome, Complement factor H mutation, Eculizumab, Newborn, MUTATIONS
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Atypical hemolytic uremic syndrome (aHUS) is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Neonatal cases are extremely uncommon. Plasma therapy is the first choice therapy in patients with aHUS based on the belief of an underlying complement dysregulation. Alternatively, eculizumab, which targets complement 5, is used to block complement activation.